Tregalizumab

Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3].

[1] Knig M, et al. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol. 2016 Jan 25;7:11. DOI:10.3389/fimmu.2016.00011
[2] Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep. 2015 Dec 16;5:18308. DOI:10.1038/srep18308
[3] Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405. DOI:10.1038/icb.2014.102